TRENDING: You Don't Have To Dig Far To Cash In On Rare Earths Novo Nordisk (NVO) kicked off a new battle with Pfizer (PFE) on Thursday by making an unsolicited $6.5 billion bid for obesity-focused takeover target, Metsera (MTSR). The bid sent shock waves through Wall Street. "You wouldn't have expected a GLP-1 incumbent to be bidding here," Evercore ISI analyst Umer Raffat said in a report to clients. "But you know what the bigger surprise is? That Novo is basically offering a 50% termination fee." Pfizer a ...